Genomenon and OmniTier Partner to Bring Mastermind’s Evidence Sources to CompStor Insight | News

0

ANN ARBOR, Mich., January 4, 2022 / PRNewswire-PRWeb / – Genomenon®, Inc., an AI-driven genomics company, announced a partnership with OmniTier, which includes the integration of Mastermind® genomic search engine in their premises based CompStor Insight® genomic analysis platform. This integration will allow CompStor® users to preview the number of published articles related to their research and easily create links to view the evidence in Mastermind.

OmniTier’s CompStor® genomic analysis platform uses proprietary Memory-Accelerated Compute and Storage (MACS) technologies to accelerate secondary and tertiary analysis on standard CPU hardware without the need for GPUs or FPGAs, which are expensive and technically difficult to support. Locating secondary and tertiary analytics on-premise rather than in the cloud enables organizations to benefit from up to 75% reduction in patient data storage costs, along with increased control and security on their data. Additionally, OmniTier has shown that by using CompStor’s automated workflows, Genome Centers can increase the number of patients that can be analyzed by 50 to 100 times, compared to manual analysis.

“Our customers have asked us to partner with Genomenon to provide them with access to the world’s most comprehensive source of genomic variant literature. Said Dr Hemant Thapar, CEO of OmniTier. “With this partnership, we will bring the power of Mastermind’s evidence-based variant research to the rapid, inexpensive, on-site variant interpretation of CompStor, designed to expand genomic screening at an affordable cost.”

Genomenon’s Mastermind® genomic search engine supports variant interpretation efforts for cancer and genetic diseases using an AI-based approach to relate patient genetic data to relevant evidence from the scientific literature. As the world’s most comprehensive source of genomic literature in the field of variant interpretation, Mastermind is used by over 1,000 diagnostic laboratories and integrated with 18 decision support platforms and reference databases. clinical grade around the world.

“We are delighted to announce a partnership with OmniTier, an organization that lowers the cost of genomic analysis for traditional clinical diagnostic and screening centers. ” noted Mike klein, CEO of Genomenon. “With this partnership, users of OmniTier’s CompStor Insight will be able to connect directly to relevant Mastermind articles when investigating specific variants of interest.”

Mastermind support will be available to all CompStor Insight users in January 2022.

CompStor® and CompStor Insight® are registered trademarks of OmniTier, Inc.

Mastermind® is a registered trademark of Genomenon, Inc.

About Genomenon, Inc.

Genomenon is an AI-driven genomics company that organizes global genomic knowledge to connect patient DNA to scientific research in the diagnosis and development of treatments for patients with rare genetic diseases and cancer.

Genomenon was named Global Company of the Year in Clinical Genomic Interpretation by Frost & Sullivan.

For more information visit Genomenon.com

About OmniTier, Inc.

OmniTier develops advanced AI and data acceleration technologies as well as proprietary genomic analysis algorithms and workflows. These are integrated with the company’s high-capacity genomic analysis devices and solutions for clinical and academic research, population studies, pharmaceuticals and consumer genomics applications. Founded in February 2015, the company is headquartered in Bay area, California United States.

For more information visit OmniTier.com

Media contact

Candace Chapman, Genomenon, 7342195175, [email protected]

SOURCE Genomene


Source link

Share.

Comments are closed.